PMID: 9682280Jul 31, 1998

Study on the suitability of a rat model for tardive dyskinesia and the preventive effects of various drugs

Progress in Neuro-psychopharmacology & Biological Psychiatry
H TakeuchiS Miura


1. Male Sprague-Dawley rats (weighing 260-300 g) were administered 1.5 mg/kg of haloperidol (HPD) intraperitoneally once daily for 28 days to produce an animal model for tardive dyskinesia (TD). The daily administration of HPD significantly increased the frequency of involuntary orofacial movements (chewing movements, tongue protrusions and buccal tremors). 2. Its suitability as a model for TD was assessed in terms of the therapeutic effects of 6 drugs [trihexyphenodyl hydrochloride(THP), clonazepam(CZP), sodium valproate(VPA), alpha-tocopherol(Vit E), ritanserin(RS) and propranolol hydrochloride(PPL)]. These drugs were also used concomitantly with HPD to study their preventive effect. 3. As for the therapeutic effects of the drugs, both the single and the 14-day daily administrations of CZP as well as of VPA significantly suppressed the chewing movements. The results were mostly consistent with the effect of each drug on human TD, indicating this would be an excellent model for TD in terms of the drug responsiveness. 4. The concomitant administration of RS from the start of HPD administration significantly suppressed the appearance of chewing movements. The concomitant administration of Vit E for 42 days also suppressed chewin...Continue Reading


Jan 1, 1979·The American Journal of Psychiatry·G ChouinardJ N Nestoros
Feb 1, 1979·The American Journal of Psychiatry·G ChouinardL Annable
Dec 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·C PerrisH Fröberg
Jul 6, 1978·Psychopharmacology·J M SmithL J Waterman
Feb 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·M Linnoila, M Viukari
Apr 1, 1990·The American Journal of Psychiatry·G K ThakerC A Tamminga
Dec 1, 1989·Journal of Clinical Psychopharmacology·W C WirshingG Bartzokis
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Wolfarth, K Ossowska
Nov 1, 1986·Biological Psychiatry·R YassaG Schwartz
Feb 1, 1981·The American Journal of Psychiatry·A BobruffP Moore
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·G Chouinard, S Steinberg
Sep 1, 1993·The American Journal of Psychiatry·L A AdlerB Angrist


Jun 15, 2005·Pharmacology, Biochemistry, and Behavior·Marilise E BurgerJ B Rocha
Jun 12, 2003·Behavioural Brain Research·Marcello F PeixotoR Frussa-Filho
Jan 24, 2004·Behavioural Brain Research·Giorgio MarcheseLuca Pani
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vanessa C AbilioR Frussa-Filho
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marilise E BurgerJ B Rocha
Dec 8, 2011·Multiple Sclerosis : Clinical and Laboratory Research·T ChitnisInternational Pediatric Multiple Sclerosis Study Group
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo

Related Concepts

Dyskinesia, Medication-Induced
Parenteral Infusion
Antipsychotic Effect
Rats, Holtzman
Anti-Dyskinesia Agents

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here